



Major shareholder announcement

On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozyymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of a statutory merger of the two companies (the "Combination"), was successfully completed. Reference is made to Novozymes' company announcement no. 2 of January 29, 2024.

January 29, 2024
Company announcement No. 03

Pursuant to Section 30 of the Danish Capital Markets Act, Novozymes hereby announces that Novo Nordisk Fonden has on its own behalf and on behalf of its wholly owned subsidiary Novo Holdings A/S notified Novozymes, that as of completion of the Combination on January 29, 2024, Novo Nordisk Fonden and Novo Holdings A/S, indirectly and directly, respectively, holds a total of 53,743,600 Novozymes A-shares (nominally DKK 107,487,200) and 58,048,725 Novozymes B-shares (nominally DKK 116,097,450) corresponding to 23.87% of the entire issued share capital and 62.55% of the total voting rights in Novozymes.

Contact information

Investor Relations

Tobias Bjorklund	+45 3077 8682	tobb@novozymes.com
Anders Enevoldsen	+45 5350 1453	adev@novozymes.com

Media Relations

Lina Danstrup	+45 3077 0552	lind@novozymes.com
---------------	---------------	--

About Novozymes

Novozyymes is the world leader in biological solutions. Together with customers, partners and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. www.novozymes.com

Novozyymes A/S

Krogshoejvej 36
2880 Bagsvaerd
Denmark

Phone: +45 4446 0000